Trial Profile
A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Idecabtagene vicleucel (Primary) ; Cyclophosphamide; Fludarabine; Lenalidomide
- Indications Multiple myeloma
- Focus Proof of concept; Therapeutic Use
- Acronyms KarMMa-2
- Sponsors Celgene Corporation
- 07 Feb 2024 Planned primary completion date changed from 18 Dec 2023 to 31 Jul 2025.
- 26 Jan 2024 According to Bristol Myers Squibb media release , supplemental Biologics License Application for Abecma in earlier lines of therapy for triple-class exposed relapsed and refractory multiple myeloma is currently under review by the U.S. Food and Drug Administration (FDA), and the Oncologic Drugs Advisory Committee of the FDA will convene a meeting to review data from KarMMa-3 supporting the application.
- 26 Jan 2024 According to Bristol Myers Squibb media release , European Commission (EC), which has t.he authority to approve medicines for the European Union (EU), will now review the CHMP recommendation